M acular oedema is the most common cause of visual loss in patients with diabetic retinopathy and its prevalence in the diabetic population has increased approximately fivefold over the past 10 years, from 0.4% to 2.1%. 1 The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated the benefit of a specific strategy of laser treatment on reducing the risk of moderate visual loss in eyes with clinically significant macular oedema (CSMO). 2 Treatment with a grid pattern in the parafoveal region up to and including the edge of the foveal avascular zone in case of diffuse thickening has also been advocated in non-randomised series. 3 4 However, the beneficial effect of laser photocoagulation is associated with severe destruction of retinal photoreceptors and considerable side effects, such as post-treatment atrophic scarring causing paracentral dense scotomas, generalised loss of the central 10˚threshold sensitivity, choroidal neovascularisation, and subfoveal fibrosis. [5] [6] [7] [8] [9] [10] [11] Moreover, a significant lateral spread of retinal pigment epithelium (RPE) atrophy may occur over time thus impairing visual function even if visual acuity (VA) is relatively preserved. 8 12 These potential complications may also negatively affect the decision to apply additional laser treatments whenever required.
Recently, some authors have shown that barely perceivable very light threshold treatment and non-visible end point subthreshold treatment promoted resolution of CSMO in small uncontrolled series. [13] [14] [15] This therapeutic effect has been correlated with the selective treatment of the RPE and subsequent restoration of its barrier function and production of growth factors. [16] [17] [18] [19] [20] Among these, the pigment epithelium derived factor (PEDF) has been shown to have a strong antiangiogenic activity and to be upregulated after photocoagulation. [21] [22] Based on these data, conventional ETDRS-like laser burns may not be necessary in the treatment of CSMO. When treating or re-treating eyes with CSMO and leaking abnormalities close to the foveal centre or diffuse macular thickening, very light laser burns may have the theoretic advantage of producing less invalidating paracentral scotomata or significant reduction in the central sensitivity. We present here results of a prospective, randomised pilot trial comparing the effectiveness of barely visible or ''light'' laser treatment versus conventional or ''classic'' laser photocoagulation in CSMO.
METHODS
Patients were enrolled from 1 September 2001 to 30 November 2002. Eligibility criteria included a diagnosis of either type 1 or type 2 diabetes mellitus and non-proliferative diabetic retinopathy with CSMO documented by slit lamp contact lens biomicroscopy, as defined by the ETDRS, 3 and confirmed by optical coherence tomography (OCT). Increased macular thickness was established if the foveal thickness (FTH), defined as the mean thickness of the central 1 mm diameter disc of the retinal map, exceeded two SD the mean normal value (that is, .210 mm). 23 24 Other inclusion criteria were haemoglobin A 1c equal or less than 10%, diastolic blood pressure less than 90 mm Hg, and visual acuity of at least 20/200 on the ETDRS chart. Patients with previous laser treatment, proliferative diabetic retinopathy, history of retinal detachment, glaucoma or any other clinically relevant ocular disease, cataract extraction or lens implantation within the past 12 months, or significant media opacities were excluded. The study was conducted according to the tenets of the Declaration of Helsinki and all subjects gave informed consent after the intent of the study had been explained.
At the baseline examination, an independent examiner refracted both eyes, measured distance visual acuity and contrast threshold using ETDRS visual acuity chart at 4 metres and Pelli-Robson charts at 1 metre, respectively. Best corrected visual acuity was scored based on the total number of correct letters identified at 4 metres plus 30. 25 The first examination also included automated static threshold perimetry, stereo fundus photography, fluorescein angiography (FA), and OCT. If FA disclosed a macular area of nonperfusion at least twice as large as the foveal avascular zone, patients were excluded from the study. Automated static threshold perimetry was performed using the Humphrey field analyser (Humphrey-Allergan Medical Instruments, Irvine, CA, USA) 10-2 program. The mean deviation (MD) over the central 10˚was recorded. OCT scans were obtained using the OCT 2000 scanner (Zeiss Humphrey Instruments, Dublin, CA, USA) with the A5 version software. OCT scanning was performed by selecting the ''radial lines'' scan pattern, which acquires six linear scans 6 mm long centred on the fovea at equally spaced angular orientation. Acceptable scans were automatically analysed by the OCT computer software and retinal thickness maps were generated. Images were judged to be ''acceptable'' on the basis of the following acceptance criteria: good demarcation of the vitreoretinal and chorioretinal interface allowing for a correct identification of the two interfaces by the software and absence of artefacts caused by eye motion or unstable fixation. The FTH was recorded for analysis from the retinal thickness maps.
Patients who were believed to satisfy all eligibility criteria were assigned randomly at enrolment to receive ''classic'' or ''light'' laser treatment. If a patient had both eyes simultaneously eligible for the study, the right eye was assigned randomly to ''classic'' or ''light'' laser treatment and the left eye received the opposite assignment. All the visits and tests were performed by the same masked examiners (AP, MDB).
Photocoagulation was performed by the same surgeon (FB) using a Nd:YAG 532 nm (frequency doubled) green laser. ''Light'' laser treatment differed from ''classic'' in that the energy employed was the lowest capable to produce barely visible burns at the level of the retinal pigment epithelium. For primary treatment with ''classic'' photocoagulation, 47 (SD 26) spots were applied with power ranging between 100 mW and 250 mW (median 140 mW), and for primary treatment with ''light'' photocoagulation, 92 (SD 36) spots were applied with power ranging between 50 mW and 100 mW (median 50 mW). Follow up visits were performed every 3 months after treatment and included a protocol refraction, best corrected visual acuity and contrast threshold measurement, fundus biomicroscopy, FA, and OCT. Automatic static threshold perimetry of the central 10˚was performed at the 3 month and 12 month follow up visit. Supplemental treatment with the same protocol of the primary treatment was considered at each visit in those eyes with treatable lesions on FA and either increased foveal thickening on fundus examination or persistent foveal thickening and decreased vision. For supplemental treatment, 45 (SD 10) spots were applied in ''classic'' group, and 106 (SD 44) spots were applied in the ''light'' group. The study included all patients who completed the 12 month follow up examination.
The primary efficacy outcome was the proportion of patients with significant decrease in FTH on OCT retina thickness maps. A significant change in FTH was defined as a change greater than 10%, which is slightly higher than the reproducibility of the instrument (that is, reproducibility of plus or minus 6%) 26 in an attempt to exclude changes caused by spontaneous inter-visit variability. Secondary efficacy outcomes included the proportion of patients with reduction elimination of CSMO on biomicroscopy and fluorescein leakage on FA compared with baseline examination at 3, 6, and 12 months after study entry, the proportion of eyes that experienced a visual gain or loss of five or more letters 
RESULTS
A total of 29 eyes of 24 patients were assigned randomly to ''classic'' or ''light'' laser photocoagulation; 14 eyes were assigned to ''classic'' and 15 to ''light'' laser treatment. Five patients were treated bilaterally and 19 patients were treated unilaterally. OCT data were not available for one eye in the ''light'' group; therefore it was excluded from OCT data analysis. Baseline variables for each group are given in table 1. Systemic, functional, and morphological characteristics were similar and not statistically different between the two groups. Table 2 summarises the results at 12 months for individual patients. Table 3 compares the outcome measurements at 3, 6, and 12 months between the two study groups. No statistically significant differences could be found for any of the outcome measurements except for the proportions of eyes that experienced a visual gain of five or more letters at 6 months, which was larger in the ''light'' group. The average FTH in both groups did not change significantly from baseline at any follow up visit. The initial median visual acuity of 20/32 in both groups remained unchanged at 12 months. At the 3, 6, and 12 month follow up, five (36%), seven (50%), and seven (50%) of 14 eyes treated with ''classic'' and four (29%), six (43%), and six (43%) of 14 eyes treated with ''light'' laser had a decrease of FTH on OCT (p = 1, 0.50 and 0.79, respectively, Fisher's exact test). At 12 month follow up, five (36%) of 14 eyes treated with ''classic'' and five (33%) of 15 eyes treated with ''light'' laser showed one line or more improvement in the visual acuity and two (14%) in the ''classic'' group and two (13%) eyes in the ''light'' group showed one line or more decrease in the visual acuity (p = 1, Fisher's exact test). The average MD decrease over the central 10˚at 12 months after ''classic'' and ''light'' laser treatment was 0.04 (SD 1.39) dB and 0.03 (SD 1.84) dB, respectively (p = 0.99, independent samples test). The number of local losses greater than 5 dB at each test point of the central 10˚, suggestive of post-treatment paracentral scotomata, was 5.00 and 4.78 in the ''classic'' and ''light'' laser treatment group, respectively, at 12 months (p = 0.40, Mann-Whitney U test). One and three eyes were retreated at 3 months and four and three eyes at 6 months in the ''classic'' and ''light'' treatment group, respectively (p = 0.60 and 0.68, respectively, Fisher's exact test).
CASE REPORT
A 55 year old man presented with a 8 year history of type 2 diabetes mellitus and non-proliferative diabetic retinopathy in both eyes. On examination, his visual acuity was 20/50 in the right eye and 20/64 in the left eye. Fundus biomicroscopy revealed diffuse retinal thickening in both eyes (figs 1A, 2A). FA showed extensive perifoveal leaking microaneurysms bilaterally (figs 1B, 2B). OCT retina thickness maps were similar in both eyes and displayed severe diffuse macular thickening (figs 1C, 2C). Two sessions of ''classic'' and ''light'' laser treatment were applied to the right and left eye, respectively, at study entry and after 6 months. The degree and extent of retinal and RPE whitening produced by laser burns, which were greater in the right eye, were documented immediately after the first laser session by red-free photographs (figs 1D, 2D). One year later his visual acuity had decreased to 20/80 in the right eye and improved to 20/50 in the left eye. The fundus examination disclosed marked decrease in foveal thickness in both eyes and multiple laser scars, which where more prominent and partly hyperpigmented in the right eye ( fig 1E) . FA disclosed a significant reduction of late leakage in both eyes (figs 1F, 2F). The OCT retinal thickness map documented a marked decrease of foveal thickening bilaterally (figs 1G, 2G). The central 10˚MD decreased from 25.4 dB to 23.45 dB in the right eye and from 25.9 dB to 23.60 dB in the left eye (figs 1H, 2H). The number of paracentral scotomata was six and two in the right and left eye, respectively.
DISCUSSION
Recent reports have suggested that the energy employed by the ETDRS in patients with CSMO may not be necessary to obtain a therapeutic effect and that these patients may be overtreated. [13] [14] [15] We designed this prospective, randomised pilot trial specifically to determine whether a significant difference existed between ''classic'' and ''light'' laser photocoagulation for CSMO and to assess the feasibility of a definite trial. Since visual acuity remains stable for a rather long time in the majority of patients with CSMO, regardless of treatment, the detection of small differences in the proportions of eyes losing vision requires large sample sizes and a long follow up time. Therefore, we used as our primary outcome a morphological parameter, which has been shown by the ETDRS to be useful in demonstrating a beneficial treatment effect. Biomicroscopic/photographic evaluation of macular oedema is semi-quantitative at best, while OCT retinal thickness measurements are objective, quantitative, and reproducible. [26] [27] [28] [29] In our study, OCT examinations were performed at every visit by an experienced independent examiner who accepted only scans fulfilling well defined acceptance criteria. Since it has been shown that in eyes undergoing grid laser photocoagulation the average threshold sensitivity across the central 10˚significantly decreases, 5 we also measured the perimetric central sensitivity in order to identify theoretical differences of the effect of the two treatments on the central visual field.
The results of this randomised trial suggest that there is no significant difference between eyes with CSMO treated with either ''classic'' or ''light'' laser treatment within the first year. However, it is possible that significant differences might have been identified if a larger sample was used or follow up was continued beyond 1 year. In particular, the greater gain in mean number of letters, larger decrease in mean FTH, and greater proportion of eyes with reduction in CSMO on biomicroscopy in the ''classic'' group at 1 year, though not reaching statistical significance, may suggest a trend towards a larger beneficial effect from ''classic'' treatment. On the other hand, a significantly larger number of patients experiencing a visual gain in the ''light'' group at 6 months may suggest an earlier benefit from this treatment, which might decrease after 6 months. Also, the failure to detect a significant difference in change in MD from baseline and in number of scotomata between the two treatment groups at 1 year could depend upon the fact that the central 10˚sensitivity showed no significant decrease following ''both'' laser treatments, in contrast with the findings reported by Striph et al. 5 This may be because of the application of ''lighter'' intensity and fewer burns even in the ''classic'' group either because of a different technique or because fewer eyes with diffuse CSMO requiring extensive treatment were included in our study. Moreover, a more sensitive test, such as the microperimetry, might have been better in identifying differences between treatments in terms of focal losses on the visual field, since the point density of the central 10-2 test may not be sufficient to detect all the localised defects.
We also found a discrepancy between the number of eyes with reduction of CSMO based on biomicroscopic examination and OCT in the ''classic'' group. This finding was the result of the resolution of paracentral oedema and persistence of central foveal thickening in three patients (patients 6, 9, 10, in table 2), as confirmed by reviewing their retinal thickness maps, which revealed a marked decrease in the paracentral areas of the map but not in the central region.
In conclusion, this study, although underpowered and unlikely to yield definite conclusions as most pilot trials, seems to rule out large differences between the two treatments. Given the potential complications from the ''classic'' ETDRS level treatment, in particular the relatively high risk of invalidating paracentral scotomata, lighter intensity laser modalities should be investigated. Our preliminary data, suggesting a similar therapeutic effect between ''classic'' and ''light'' laser treatment, supports the further investigation of ''light'' laser photocoagulation with a larger equivalence trial. ''Light'' v ''classic'' laser treatment for CSMO
